Literature DB >> 15273155

Challenges in designing animal studies to detect antagonism of polyene activity.

Russell E Lewis, Dimitrios P Kontoyiannis, Dimitrios P Kantoyiannis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15273155      PMCID： PMC478508          DOI： 10.1128/AAC.48.8.3211-3212.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  9 in total

1.  Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy.

Authors:  D P Kontoyiannis; R E Lewis; N Sagar; G May; R A Prince; K V Rolston
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 2.  Use of amphotericin B with azole antifungal drugs: what are we doing?

Authors:  A M Sugar
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

3.  Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.

Authors:  T F Patterson; W R Kirkpatrick; M White; J W Hiemenz; J R Wingard; B Dupont; M G Rinaldi; D A Stevens; J R Graybill
Journal:  Medicine (Baltimore)       Date:  2000-07       Impact factor: 1.889

4.  Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.

Authors:  Russell E Lewis; Randall A Prince; Jingduan Chi; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

5.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

6.  Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism.

Authors:  A Schaffner; A Böhler
Journal:  Mycoses       Date:  1993 Nov-Dec       Impact factor: 4.377

7.  The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis.

Authors:  A Schaffner; P G Frick
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

8.  In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.

Authors:  C Lass-Flörl; G Kofler; G Kropshofer; J Hermans; A Kreczy; M P Dierich; D Niederwieser
Journal:  J Antimicrob Chemother       Date:  1998-10       Impact factor: 5.790

9.  Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories.

Authors:  Laura K Najvar; Anthony Cacciapuoti; Steve Hernandez; Judith Halpern; Rosie Bocanegra; Maya Gurnani; Frederick Menzel; David Loebenberg; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.